Vet Pathol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hershey, A. E.
Right arrow Articles by Helfand, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hershey, A. E.
Right arrow Articles by Helfand, S. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Vet Pathol 42:805-811 (2005)
© 2005 American College of Veterinary Pathologists

Aberrant p53 Expression in Feline Vaccine-associated Sarcomas and Correlation with Prognosis

A. E. Hershey, R. R. Dubielzig, M. L. Padilla and S. C. Helfand

Departments of Medical Sciences (AEH, MLP, SCH ), Comprehensive Cancer Center (SCH), and Pathobiological Sciences (RRD), University of Wisconsin–Madison, School of Veterinary Medicine, Madison, WI


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 Acknowledgements
 References
 
Eighty spontaneously occurring feline vaccine-associated sarcomas (VAS) were evaluated to determine the immunohistochemical expression of the tumor suppressor gene p53. Sixty-five of 80 VAS (81%) exhibited positive immunoreactivity with Mab240, a murine monoclonal antibody that specifically recognizes mutated p53. Only 44 of 81 tumors (55%) were positive with rabbit polyclonal antibody CM-1. CM-1 often yielded nonspecific staining of nonneoplastic tissues. Nonspecific staining was greatly reduced or absent with Mab240. Cytoplasmic staining for p53 was a consistent pattern of VAS, occurring in 44% of tumors evaluated. Cats with tumors that exhibited cytoplasmic p53 had significantly shorter time to tumor recurrence compared to those cats with tumors that exhibited nuclear p53 staining (P = 0.0284), but no significant difference in survival outcome was observed. Immunohistochemical detection of p53 offers a prognostic tool for VAS, and, because abnormal p53 expression appears to be a common feature of feline VAS, molecular targeting of mutant p53, may offer a promising new therapeutic opportunity for this cancer.

Key words: Cats; fibrosarcoma; immunohistochemistry; p53; tumor suppressor genes.

Effective treatment of vaccine-associated sarcomas (VAS) in the cat remains a challenging problem. Compared with sarcomas not associated with vaccination, VAS exhibit anaplasia, rapid growth, ulceration, and necrosis.3,5,21 Additionally, VAS are often poorly encapsulated, making complete excision difficult and local recurrences common.21 Surgery continues to be the mainstay of treatment; however, a recent study suggests that surgery alone is curative in only a small percentage of cases and only where radical excision (i.e., amputation) can be achieved.15 Radiation therapy and chemotherapy have been used as adjuncts to surgery, and doxorubicin-based chemotherapy has been shown to delay the onset of tumor recurrence but not to extend overall survival time.29 Thus, novel therapeutic approaches to complement conventional treatment warrant investigation. An understanding of the molecular basis of malignant transformation of these tumors in cats is critical to the development of novel treatment approaches.

Considerable interest has been generated regarding the role of mutation of the tumor suppressor gene p53 in the development of VAS. The tumor suppressor gene p53 encodes for a nuclear protein that plays a key role in the regulation of the cell cycle. In response to DNA damage, wild-type p53 increases, which prevents the cell from progressing through the cell cycle, allowing for DNA repair prior to continued cell replication.28,39 Should the damage to the DNA be too great, p53 induces apoptosis, thereby preventing defects in the genetic code from being passed on to subsequent generations.13,28,39 Cells in which p53 is absent or mutated are allowed to proceed unregulated through the cell cycle, giving rise to aberrant clones and potentially to malignant transformation.

Most mutations of p53 occur within several "hot spot" locations of the genome, particularly exons 5–8, which are clearly linked to tumorogenesis.11 Point mutations of p53, which confer an alteration in the structural conformation of the gene, are most common. This conformational change results in a longer half-life of the protein, allowing accumulation of the mutant p53 within the nucleus of affected cells; this accumulation can then be detected by immunohistochemical methods.16 In contrast, wild-type gene p53 is not detectable by immunohistochemistry because of its short half-life.

Dysregulation of p53 expression has been demonstrated in a variety of human tumors and may be of prognostic significance. Association between p53 mutations and prognosis has been reported for several human malignancies, including breast cancer,17,36,37 osteosarcoma,25 thyroid cancer,2 and soft tissue sarcomas.19,28 A recent study by Sagartz et al. was able to demonstrate a correlation between alterations in p53 expression and predicted aggressive tumor behavior in osteogenic tumors of dogs.31 Expression of mutant p53 has been reported in feline hematopoietic and solid tumors.22–25 However, these reports in feline tumors have been sporadic, and to date no associations have been made between overexpression of p53 and observed tumor behavior.

This study was initiated to evaluate whether alterations in p53 expression occur in spontaneously occurring VAS in cats, utilizing a panel of anti-p53 antibodies for the immunohistochemical detection of abnormal p53. In humans, studies suggest that a combination of antibodies is a more sensitive method of p53 detection and provides more prognostically relevant information than a single antibody used alone.4 Correlation between p53 immunoreactivity and clinical outcome was demonstrated in a subset of cats.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 Acknowledgements
 References
 
Tumor acquisition

Eighty formalin-fixed, paraffin-embedded VAS from 80 cats were evaluated. A subset of tissues were from cats that had been part of a previous retrospective study.15 The remaining tissues were obtained from client-owned cats that presented for surgical excision or incisional biopsy of their tumors at the University of Wisconsin–Madison Veterinary Medical Teaching Hospital. Additionally, three cell culture lines (courtesy of Dr. Greg MacEwen and Jennifer Carew) were evaluated for p53 expression.

Immunohistochemistry

Immunohistochemical detection of p53 expression was performed on deparaffinized sections using the streptavidin–biotin–peroxidase complex method. The initial panel of anti-p53 primary antibodies consisted of rabbit polyclonal antibody CM-1 (Biocare Medical, Walnut Creek, CA) and four monoclonal antibodies: 1801, DO7, DO1, and 240 (Oncogene Research Products, San Diego, CA). Three of the monoclonal antibodies (DO1, DO7, 1801) failed to produce immunoreactivity in any of the feline tissues; this was presumed to be attributable to lack of sufficient sequence homology with feline p53. The final panel of anti-p53 antibodies included the polyclonal antibody CM-1, which recognizes wild-type and mutant p53, and monoclonal antibody 240 (Mab240), a murine monoclonal antibody of the IgG1 isotype that specifically recognizes mutant p53.

Five-micrometer paraffin-embedded sections were placed on Kling-on HIER supercharged slides (Biocare Medical), incubated overnight in a 37°C dry heat oven and then deparaffinized by incubations of 5 minutes each at 25°C in xylene, decreasing concentrations of ethanol, and water. Endogenous peroxidase was blocked in Peroxidazed1 (Biocare Medical) for 5 minutes. The sections were then boiled in a commercial steamer containing either 10 mM sodium citrate buffer at a pH of 6.0 (CM-1) or TUF/Retrievall (Mab240, Signet Laboratories, Dedham, MA) for 35 minutes. Nonspecific staining was blocked using 10% goat serum with Tween 20 in phosphate buffered saline (PBS) (Background Eraser, Biocare Medical) for 5 minutes at room temperature. After pretreatment, the sections were incubated for 1 hour at room temperature with the anti-p53 antibodies at a dilution of 1:200 (CM-1) or 1:150 (Mab240). Dilutions were made in PBS. Following incubation with primary antibody, the sections were successively incubated with anti-rabbit/anti-mouse biotinylated secondary antibody (Biocare Medical) for 10 minutes at room temperature and streptavidin conjugated with peroxidase (Biocare Medical) also for 10 minutes at room temperature in a humidity chamber. The sections were then developed with 3,3'-diaminobenzidine tetrachloride, prepared according to the manufacturer's instructions, for 5 minutes at room temperature. The slides were washed in distilled water and counterstained for 1 minute with Tacha's hematoxylin (Biocare Medical). Slides were washed in tap water, dehydrated in ethanol, and cleared with xylene, and coverslips were mounted with Permount (Fisher Scientific, Pittsburgh, PA)

The positive control was a paraffin-embedded section of a human colon carcinoma cell line known to be positive for abnormal expression of p53 and provided by Biocare Medical. Additional sections of each tumor block were processed with omission of the primary antibody as a negative control.

p53 immunostaining was evaluated by light microscopy using a 40x lens. A positive result was scored if there was nuclear or cytoplasmic staining of the majority of malignant fibroblasts of greater intensity than surrounding nonneoplastic tissues. If there was no stain or stain of equal or lesser intensity than the adjacent nonneoplastic tissues, the result was considered negative.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 Acknowledgements
 References
 
Eighty sarcomas were assessed for immunoreactivity to p53. Nonspecific staining of hair follicles, epidermis, and muscle was often observed with the CM-1 polyclonal antibody. The presence of nonspecific tissue staining was dramatically decreased or absent with Mab240.

Overall, 81% (n = 65) of the tumors exhibited positive staining with Mab240. By contrast, 55% (n = 44) of tumors were positive with CM-1. Thirty-eight percent (n = 29) of the positive-staining tumors exhibited nuclear immunoreactivity for p53 with both antibodies. Of these tumors, two exhibited cytoplasmic immunoreactivity in addition to nuclear immunoreactivity with CM-1, whereas 14 tumors exhibited both nuclear and cytoplasmic immunoreactivity with Mab240 (Fig. 1). Three tumors that demonstrated positive nuclear staining with CM-1 exhibited positive cytoplasmic staining with Mab240. Sixteen percent (n = 12) of tumors exhibited only cytoplasmic staining with both antibodies. Twenty-six percent (n = 21) of tumors that were considered negative with CM-1 demonstrated convincing positive cytoplasmic staining with Mab240 (Fig. 2). Nineteen percent (n = 15) of tumors stained with Mab420 and 45% (n = 36) stained with CM-1 were considered negative with both antibodies (Table 1). In those tumors demonstrating positive immunoreactivity for p53, nonneoplastic mesenchymal cells peripheral to the tumor cells also exhibited positive staining in many samples, especially with Mab240 (Fig. 3).



View larger version (106K):
[in this window]
[in a new window]
  		Fig. 1. Human colon carcinoma and feline vaccine-associated sarcoma stained with Mab240.
Fig. 1A. Positive control; human colon carcinoma; note only nuclei stain brown.
Fig. 1B. Negative control; feline vaccine-associated sarcoma. Tissue is processed with omission of the primary antibody.
Fig. 1C. Same tumor as in Fig. 1B, with application of primary antibody. In this tumor, both the nuclei and the cytoplasm exhibit immunoreactivity. Immunhistochemistry was performed with streptavidin–biotin–peroxidase complex method, developed with 3,3'-diaminobenzidine tetrachloride, and counterstained with Tacha's hematoxylin.

 


View larger version (138K):
[in this window]
[in a new window]
  		Fig. 2. Feline vaccine-associated sarcoma, demonstrating contrasting results between CM-1 and Mab240.
Fig. 2A. Tumor exhibiting positive cytoplasmic staining with Mab240.
Fig. 2B. Identical tumor stained with CM-1. No immunoreactivity, either nuclear or cytoplasmic, is present. Immunhistochemistry was performed with streptavidin–biotin–peroxidase complex method, developed with 3,3'-diaminobenzidine tetrachloride, and counterstained with Tacha's hematoxylin. Bar = 100 µ.

 

View this table:
[in this window]
[in a new window]
  		Table. 1 Results obtained from immunohistochemical staining of paraffin-embedded vaccine-associated sarcomas in cats.

 


View larger version (114K):
[in this window]
[in a new window]
  		Fig. 3. Feline vaccine-associated sarcoma stained with Mab240. Histologically normal mesenchymal cells peripheral to the tumor in Fig. 2 exhibit positive immunoreactivity with Mab240, suggesting the possibility of a "field cancerization" effect in this cat. Immunhistochemistry performed with streptavidin–biotin–peroxidase complex method, developed with 3,3'-diaminobenzidine tetrachloride, and counterstained with Tacha's hematoxylin.

 
Of the three cell lines evaluated, one demonstrated negative immunoreactivity, one positive cytoplasmic staining, and one positive nuclear plus cytoplasmic staining. The negative sample had previously exhibited positive nuclear immunoreactivity on the paraffin section of the tumor from which the cell line was derived. However, the results for the other two tumors were consistent with those obtained on the paraffin sections. The positive control stained appropriately and the negative controls failed to stain as expected.

In the subset of cats (n = 61) for which the clinical outcome was known,15 there was no significant difference in time to recurrence or overall survival between p53-positive and p53-negative tumors. However, a significant difference (P = 0.0284) was determined in time to recurrence between cats exhibiting cytoplasmic p53 immunoreactivity versus nuclear p53 immunoreactivity. Those cats with positive cytoplasmic p53 staining had tumors recur earlier postsurgery (135 days) than those cats with tumors exhibiting positive nuclear staining (325 days; Fig. 4). No significant difference was observed in overall survival between cytoplasmic versus nuclear p53 staining. No significant difference was observed in either time to recurrence or overall survival between cats exhibiting positive cytoplasmic p53 staining versus those with p53 negative tumors.



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4. Kaplan-Meier curve, illustrating time to recurrence for cats with cytoplasmic expression of p53 versus cats with nuclear expression of p53. Cats with cytoplasmic p53 positive tumors had significantly earlier (135 days) time to recurrence postsurgery than cats with nuclear p53 positive tumors (325 days, P = 0.0284).

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
Acknowledgements
 References
 
Abnormal p53 expression in feline VAS appears to be a common feature of this cancer. Fifty-five percent of VAS stained positive with CM-1, a polyclonal antibody. Eighty-one percent of VAS exhibited positive immunoreactivity with Mab240, a murine monoclonal antibody that specifically recognizes mutant p53 in humans.9 On the basis of the higher percentage of tumors exhibiting positive immunoreactivity with Mab240 and the reduction in staining of nonneoplastic tissues, Mab240 must be considered superior to CM-1 for the detection of abnormal p53 in feline VAS.

Cytoplasmic staining for p53 is a consistent pattern of VAS stained with Mab240, occurring in 45% of tumors evaluated. It is possible that the large percentage of cytoplasmic staining observed with this antibody is artifactual; however, numerous studies in human tumors have confirmed abnormal cytoplasmic expression of p53 to be commonly seen in cancer. The overexpression of p53 is usually the result of a mutation, which results in an altered molecular conformation, a prolonged protein half-life, and subsequent abnormal accumulation within the cell. Variations in mutations, and thus in conformational effects1 and biological activity,12 may alter the ability of p53 to act as a transcription factor30 or to bind to heat shock protein 70 (hsp70).12 Heat shock protein 70 is a molecular chaperone molecule capable of binding to mutant p53 and consequently could regulate its accumulation, alter its subcellular localization and distribution, and result in sequestration within the cytoplasm.10,27 Cytoplasmic expression of p53 may represent a functional inactivation pattern.7 Inability of p53 to translocate to the nucleus presumably prevents its transactivating function, and subsequently its ability to act as a suppressor.26 Cytoplasmic expression of p53 has also been reported in human cancers20,33,34 and has been correlated with a poor prognosis in colorectal cancer6,34–36 and breast cancer.35 Similarly, we have demonstrated that cytoplasmic expression of p53 is associated with a worse prognosis in feline VAS. Cats with tumors that exhibited cytoplasmic p53 had significantly shorter time to tumor recurrence compared to those cats with tumors that exhibited nuclear p53 staining.

An unexpected observation was the staining of normal-appearing mesenchymal cells in the peripheral tissues of tumors demonstrating abnormal p53 expression. VAS are often poorly encapsulated, infiltrating along fascial planes. Thus, these positive-staining peripheral mesenchymal cells may represent microscopic extension from the primary tumor. However, these cells appear histologically benign in comparison to positive-staining neoplastic cells. The most interesting explanation is that these normal-appearing mesenchymal cells may represent the phenomenon of field cancerization, which predicts that precancerous lesions, under the influence of a common carcinogen, exist in histologically normal tissue adjacent to tumors.38 These lesions may proceed to develop into multiple new primary lesions and do not necessarily represent recurrence of the initial primary tumor. Field cancerization has been demonstrated in various human cancers, particularly squamous cell carcinoma of the head and neck8 and lung carcinomas.32 Preliminary work by Kanjilal and colleagues suggests that field cancerization may play an important role in the pathogenesis of VAS.38 Mutations in p53 have been identified in surrounding histologically normal tissues up to 5 cm distant from the tumor.18,38 This may have important implications for prognosis and considerations for adjuvant therapy for VAS. Alternatively, as genetic predisposition likely plays a significant role in the tumorogenesis of VAS, these cells may represent an inherent somatic defect in p53 in certain cats.

This study demonstrates the abnormal expression of p53 to be a highly associated factor of VAS in the cat. Similar to reports of various human cancers, cytoplasmic expression of p53 is associated with a worse prognosis for tumor recurrence. Immunohistochemical detection of p53 is a simple technique that may offer an important prognostic tool for clients. Additionally, because there is a high frequency of abnormal expression in feline VAS, molecular targeting of mutant p53 may offer new therapeutic opportunities for this disease, particularly in those cats with tumors exhibiting cytoplasmic p53 staining.


   Acknowledgements
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 Acknowledgements
References
 
The authors would like to acknowledge Dr. David Vail for statistical assistance and the following laboratories for submission of histologic samples: Marshfield Laboratories, Antech Laboratories, ARUP Laboratories, University of Pennsylvania Veterinary Diagnostic Laboratory, and the University of Wisconsin Veterinary Diagnostic Laboratory. This project was supported by a Companion Animal Research Grant from the University of Wisconsin–Madison School of Veterinary Medicine and by Ms. Virginia Harrington in memory of Scarlet.


   Footnotes
 
1 Present address: Integrative Veterinary Oncology, Phoenix, AZ Back

2 Present address: Oregon Cancer Center for Animals, College of Veterinary Medicine, Oregon State University, Corvallis, OR Back


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 Acknowledgements
 References
 

  1. Brandt-Rauf PW, DeVivo I, Dykes DC, Pincus MR. Conformational effects of selected cancer-related amino acid substitutions in the p53 protein. J Biomol Struct Dyn 10:253–264, 1992[Web of Science][Medline]
  2. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, Machinami R. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375–381, 1993[CrossRef][Web of Science][Medline]
  3. Doddy FD, Glickman LT, Glickman NW, Janovitz EB. Feline fibrosarcomas at vaccination and non-vaccination sites. J Comp Pathol 114:165–174, 1996[CrossRef][Web of Science][Medline]
  4. Elledge RM, Clark GM, Fuqua SAW, Yu Y-Y, Allred DC. P53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54:3752–3757, 1994[Abstract/Free Full Text]
  5. Esplin DG, McGill LD, Meininger AC, Wilson SR. Postvaccination sarcomas in cats. J Am Vet Med Assoc 202:1245–1247, 1993[Web of Science][Medline]
  6. Flamini G, Curigliano G, Ratto C, Astone A, Feretti G, Nucera P, Sofo L, Sgambato A, Boninsegna A, Crucitti F, Cittadini A. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur J Cancer 32A:802–806, 1996[CrossRef]
  7. Flamini G, Magalini S, Curigliano G, Nanni G, Boninsegna A, Agnes S, Faticato D, Castagneto M, Cittadini A. Immunohistochemical analysis of p53 protein in transplant recipients with Kaposi's sarcoma. J Cancer Res Clin Oncol 123:240–242, 1997[CrossRef][Web of Science][Medline]
  8. Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM, Miller YE. Widely dispersed p53 mutation in respiratory epithelium: a novel mechanism for field carcinogenesis. J Clin Invest 100:2133–2137, 1997[Web of Science][Medline]
  9. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602, 1990[Web of Science][Medline]
  10. Gannon JV, Lane DP. Protein synthesis required to anchor a mutant p53 which is temperature-sensitive for nuclear transport. Nature (Lond) 349:802–806, 1991[CrossRef][Medline]
  11. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878, 1994[Free Full Text]
  12. Halevy O, Michalovitz D, Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250:113–116, 1990[Abstract/Free Full Text]
  13. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442–1455, 1996[Abstract/Free Full Text]
  14. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329:1318–1327, 1993[Free Full Text]
  15. Hershey AE, Sorenmo KU, Hendrick MJ, Shofer F, Vail DM. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986–1996). J Am Vet Med Assoc 216:58–61, 2000[CrossRef][Web of Science][Medline]
  16. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 253:49–53, 1991[Abstract/Free Full Text]
  17. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109–1114, 1992[Abstract/Free Full Text]
  18. Kanjilal S, Banerji N, Fifer A, Wood C, Klausner JS, Kapur V. p53 tumor suppressor gene alterations in vaccine-associated feline sarcoma. Proc Annu Vet Cancer Soc Conf 19:48, 1999
  19. Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohashi S, Inoue H, Fukuma H. Nuclear immunoreaction of p53 protein in soft tissue sarcomas, a possible prognostic factor. Cancer 73:2499–2505, 1994[CrossRef][Web of Science][Medline]
  20. Li X, Tsuji T, Wen S, Sobban F, Wang Z, Shinozaki F. Cytoplasmic expression of p53 protein and its morphological features in salivary gland lesions. J Oral Pathol Med 24:201–205, 1995[CrossRef][Web of Science][Medline]
  21. Macy D. Vaccine associated sarcomas. Proc Annu Vet Med Forum Am Coll Vet Intern Med 12:854–856, 1994
  22. Mayr B, Heczko U, Schellander K, Schleger W, Reifinger M. Sequence of an exon of the feline p53 gene-mutation in a lymphosarcoma. Br Vet J 149:387–390, 1993[Web of Science][Medline]
  23. Mayr B, Schaffner G, Kurzbauer R, Reifinger M, Schellander K. Sequence of an exon of tumour suppressor gene—a comparative study in domestic animals: mutation in a feline solid mammary carcinoma. Br Vet J 151:325–329, 1995[Web of Science][Medline]
  24. Mayr B, Schaffner G, Kurzbauer R, Schneider A, Reifinger M, Loupal G. Mutations in tumour suppressor gene p53 in two feline fibrosarcomas. Br Vet J 151:707–713, 1995[Web of Science][Medline]
  25. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50:7950–7954, 1990[Abstract/Free Full Text]
  26. Moll UM, LaQuaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407–4411, 1995[Abstract/Free Full Text]
  27. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262–7266, 1992[Abstract/Free Full Text]
  28. Pellegata NS, Antoniono RJ, Redpath JL, Stanbridge EJ. DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc Natl Acad Sci USA 93:15209–15214, 1996[Abstract/Free Full Text]
  29. Poirier VJ, Thamm DH, Kurzman ID, Jeglum KA, Chun R, Obradovich JE, O'Brien M, Fred RM, Phillips BS, Vail DM. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med 16:726–31, 2002[CrossRef][Web of Science][Medline]
  30. Raycroft L, Schmidt JR, Yoas K, Hao M, Lozano G. Analysis of p53 mutants for transcriptional activity. Mol Cell Biol 11:6067–6074, 1992
  31. Sagartz JE, Bodley WL, Gamblin RM, Couto CG, Tierney LA, Capen CC. P53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Vet Pathol 33:213–221, 1996[Abstract]
  32. Sozzi G, Miozzo M, Tagliabue E, Calderone C, Lombardi L, Pilotti S, Pastorino U, Pierotti MA, Della Porta G. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res 51:400–404, 1991[Abstract/Free Full Text]
  33. Stenmark-Askmalm M, Stal O, Sullivan S, Ferraud L, Sun XF, Carstensen J, Nordenskjold B. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 32A:175–180, 1994
  34. Sun XF, Carstensen JM, Zhang H, Arbman G, Nordenskjold B. Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur J Cancer 32A:1963–1967, 1996
  35. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, Nordenskjold B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinomas. Lancet 340:1369–1373, 1992[CrossRef][Web of Science][Medline]
  36. Sun XF, Zhang H, Carstensen JM, Jansson A, Nordenskjold B. Heat shock protein 72/73 in relation to cytoplasmic p53 expression and prognosis in colorectal adenocarcinomas. Int J Cancer 74:600–604, 1997[CrossRef][Web of Science][Medline]
  37. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845–855, 1992[Abstract/Free Full Text]
  38. Williams L, Zinggeler J, Klausner J, Kanjilal S. Field Cancerization. Vet Cancer Soc Newsletter 22:8–9, Winter 1998–1999
  39. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell 70:523–526, 1992[CrossRef][Web of Science][Medline]
Request reprints from S. C. Helfand, Department of Clinical Sciences, Oregon Cancer Center for Animals, College of Veterinary Medicine, Oregon State University, Magruder Hall, Corvallis, OR 97331 (USA). E-mail: stuart.helfand{at}oregonstate.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hershey, A. E.
Right arrow Articles by Helfand, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hershey, A. E.
Right arrow Articles by Helfand, S. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS